PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1977715-0 1990 Prognostic potential of serum CA 125 levels in danazol-treated patients with external endometriosis: a preliminary study. Danazol 47-54 mucin 16, cell surface associated Homo sapiens 30-36 7871327-2 1994 A 42-year-old female patient with rectal endometriosis treated with danazol under CA 125, CA 19-9 and estrogen monitoring is described. Danazol 68-75 mucin 16, cell surface associated Homo sapiens 82-88 1533376-0 1992 On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Danazol 155-162 mucin 16, cell surface associated Homo sapiens 40-46 1533376-11 1992 CONCLUSIONS: The findings indicate that adhesions play a major role in the presence of CA-125 in the systemic circulation and suggest that reductions of serum CA-125 concentrations during gonadotropin-releasing hormone agonist and danazol therapy are hormonally determined. Danazol 231-238 mucin 16, cell surface associated Homo sapiens 159-165 8012438-5 1994 The administration of Danazol significantly reduced the levels of CA-125 (P < .01), and 3 months after treatment the levels of CA-125 remained significantly lower (P < .05) as compared to the respective pretreatment values. Danazol 22-29 mucin 16, cell surface associated Homo sapiens 66-72 8012438-5 1994 The administration of Danazol significantly reduced the levels of CA-125 (P < .01), and 3 months after treatment the levels of CA-125 remained significantly lower (P < .05) as compared to the respective pretreatment values. Danazol 22-29 mucin 16, cell surface associated Homo sapiens 130-136 8012438-6 1994 CONCLUSION: The results support the view that the determination of CA-125 levels may assist in (a) evaluating women with endometriosis and (b) treatment with Danazol. Danazol 158-165 mucin 16, cell surface associated Homo sapiens 67-73 1977715-1 1990 Serum levels of CA 125 in 33 patients with progressive external endometriosis who were treated with 400 mg/day of Danazol for 16 weeks were assayed for an extended period (24-40 weeks), and changes in the CA 125 pattern were analyzed. Danazol 114-121 mucin 16, cell surface associated Homo sapiens 16-22 3164281-0 1988 CA-125 is an effective marker for patients with external endometriosis and on danazol: case reports. Danazol 78-85 mucin 16, cell surface associated Homo sapiens 0-6 2509602-24 1989 Danazol and EGF inhibit the release of CA125 into culture media when standardized per cell. Danazol 0-7 mucin 16, cell surface associated Homo sapiens 39-44 2676640-0 1989 CA 125 levels in endometriosis patients before, during and after treatment with danazol or LHRH agonists. Danazol 80-87 mucin 16, cell surface associated Homo sapiens 0-6 2676640-1 1989 The levels of CA 125 in the serum of 54 patients with endometriosis were measured before, during and after treatment with Danazol or LHRH analogues. Danazol 122-129 mucin 16, cell surface associated Homo sapiens 14-20 2565317-5 1989 Although the high pretreatment level of serum CA 125 decreased after danazol treatment of 400 mg/day to within the normal limits, usually within 4 to 12 weeks, laparoscopic examinations indicated that most of the endometriosis cases were not cured until 12-16 weeks of danazol treatment. Danazol 69-76 mucin 16, cell surface associated Homo sapiens 46-52 2565317-5 1989 Although the high pretreatment level of serum CA 125 decreased after danazol treatment of 400 mg/day to within the normal limits, usually within 4 to 12 weeks, laparoscopic examinations indicated that most of the endometriosis cases were not cured until 12-16 weeks of danazol treatment. Danazol 269-276 mucin 16, cell surface associated Homo sapiens 46-52 2462793-4 1988 In patients treated with danazol (n = 10) or buserelin (n = 17), plasma CA 125 levels decreased significantly by midtherapy, remained suppressed at the end of therapy, but rebounded to near pretreatment levels 6 months after treatment was completed. Danazol 25-32 mucin 16, cell surface associated Homo sapiens 72-78 3164281-1 1988 Serum levels of CA-125 in women with external endometriosis and on danazol were assayed for an extended period, and changes in the CA-125 pattern were analyzed. Danazol 67-74 mucin 16, cell surface associated Homo sapiens 16-22 2961624-4 1988 Postoperatively, CA-125 responses to danazol, MPA, or placebo did not differ significantly from each other. Danazol 37-44 mucin 16, cell surface associated Homo sapiens 17-23 2961624-0 1988 Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery. Danazol 108-115 mucin 16, cell surface associated Homo sapiens 52-58 2961624-2 1988 The concentration of CA-125 was significantly higher in stages III + IV (66.6 +/- 22.0 [standard deviation] U/ml) than in stage I (20.9 +/- 2.3 U/ml) or II (28.4 +/- 2.8 U/ml); in stage II, the concentration was higher than in stage I. Surgical elimination of endometriosis significantly decreased the level of CA-125, as did danazol, but not medroxyprogesterone acetate (MPA), although these drugs were equal in clinical efficacy. Danazol 326-333 mucin 16, cell surface associated Homo sapiens 21-27 2961624-5 1988 During the 6-month follow-up after medication, the CA-125 concentrations tended to increase, especially in danazol-treated women. Danazol 107-114 mucin 16, cell surface associated Homo sapiens 51-57 2961624-7 1988 The ability of danazol to suppress CA-125 expression emphasizes the specific properties of this drug. Danazol 15-22 mucin 16, cell surface associated Homo sapiens 35-41 2437144-8 1986 Gonadotrophin-releasing hormone or Danatrol therapy significantly reduced the CA125 levels. Danazol 35-43 mucin 16, cell surface associated Homo sapiens 78-83 3475234-5 1987 The CA 125 levels in these patients gradually decreased after surgery and/or Danazol treatment and the levels were below 39 U/ml within four weeks. Danazol 77-84 mucin 16, cell surface associated Homo sapiens 4-10 3475378-11 1987 The serum CA125 levels were below 35 U/ml in 13 out of 15 patients (86.7%) with pelvic endometriosis treated with danazol and the change in the serum CA125 levels was closely related to the clinical course. Danazol 114-121 mucin 16, cell surface associated Homo sapiens 10-15 3475378-11 1987 The serum CA125 levels were below 35 U/ml in 13 out of 15 patients (86.7%) with pelvic endometriosis treated with danazol and the change in the serum CA125 levels was closely related to the clinical course. Danazol 114-121 mucin 16, cell surface associated Homo sapiens 150-155 23544741-10 2014 After danazol treatment the patients reported lower pain scores; in addition, CA-125 concentrations in the plasma were decreased (P<0.001), whereas VEGF concentration in the plasma increased (P=0.009). Danazol 6-13 mucin 16, cell surface associated Homo sapiens 78-84 23544741-12 2014 Danazol treatment is highly effective in relieving pain and decreasing CA-125 concentrations in the plasma. Danazol 0-7 mucin 16, cell surface associated Homo sapiens 71-77 15188832-0 2004 Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis. Danazol 53-60 mucin 16, cell surface associated Homo sapiens 81-87 15188832-1 2004 OBJECTIVE: To investigate the effects of danazol and leuprorelin acetate on CA-125 levels during treatment for endometriosis. Danazol 41-48 mucin 16, cell surface associated Homo sapiens 76-82 15188832-8 2004 Six months of danazol or leuprorelin acetate depot treatment decreased serum CA-125 levels. Danazol 14-21 mucin 16, cell surface associated Homo sapiens 77-83 15188832-9 2004 Three months after stopping danazol, CA-125 levels remained significantly lower than pretreatment levels. Danazol 28-35 mucin 16, cell surface associated Homo sapiens 37-43